Home
overview
With an ever increasing population suffering from or at risk from Diabetes, the SMi Group’s 8th Annual Diabetes Conference comes at a crucially important time within the pharmaceutical industry. In the US Diabetes is the sixth biggest killer and on average the eighth in high-income countries, evidence enough that we are at a crossroads with this disease.
In attending the SMi Group’s 8th Annual Diabetes Conference you will gain insights into which direction to now go. Industry leaders will gather for your benefit to discuss new targets, next generation drugs, gluckinase activators and expenditure genes.
Mechanisms of insulin sensitization without causing weight gain will also be discussed as will novel kinetic assays for metabolic drug discovery making your attendance at this industry leading event essential if you wish to keep up to date with your peers

5 Key Benefits of Attending

1, HEAR KEY UPDATES on novel targets for drug discovery through RNAi
2, UNDERSTAND new mechanisms of insulin sensitization without causing weight gain
3, GAIN INSIGHTS INTO the Diabetes licensing landscape
4, DISCOVER NEW WAYS into treating visceral obesity and insulin resistance
5, INVESTIGATE beta cell regeneration- the ultimate cure for Diabetes?

CONFIRMED SPEAKERS INCLUDE
  • Rebecca Taub, Vice President, Research, Metabolic Diseases, Therapeutic Area Head, F. Hoffmann- La Roche
  • Richard Carr, Senior Director, Merck
  • Dr Simon Westbrook, Associate Research Fellow, Biomarkers and Translational Biology, Pfizer
  • Dr Matthew Coghlan, Candidate Drug Delivery Team Leader, Diabetes and Drug Discovery, AstraZeneca
  • Dr Timothy Herpin, Director, Metabolic Disease Licensing, Bristol-Myers Squibb
  • Dr David Ferrick, Chief Scientific Officer and Vice President, Metabolic Research, Seahorse Bioscience

LAST YEAR’S DELEGATES INCLUDED REPRESENTATIVES FROM THE FOLLOWING ORGANISATIONS

Roche Diagnostics
Eli Lilly
Solvay
Merck
Sanofi-Aventis
Bristol-Myers Squibb
Laboratories Dr Esteve
Kowa Research Limited
Asterand

THIS EVENT IS AIMED AT THOSE WITH THE FOLLOWING JOB FUNCTIONS, INCLUDING;

Clinical Research Manager
Principal Scientist
Director, Metabolic Research
Director, Metabolic Disease Licensing
Director, Clinical Development
Director, Drug Discovery

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Timothy Herpin

Timothy Herpin, Director, Bristol-Myers Squibb

9:10 DIABETES LICENSING LANDSCAPE AND DEAL MAKING TRENDS

Timothy Herpin

Timothy Herpin, Director, Bristol-Myers Squibb

  • Recent deals and collaborations in the diabetes area
  • Licensing landscape: technologies and compounds
  • Trends in the financing and strategic development of diabetes biotech companies
  • 9:50 JANUVIA: UPDATE OF ITS SCIENTIFIC AND MEDICAL PROFILE

    Richard Carr

    Richard Carr, Senior Director, Merck Sharpe and Dohme

  • Current and upcoming targets for treating diabetes
  • Case examples
  • Challenges, benefits and limitations of these targets
  • 10:30 Morning Coffee

    11:00 EMERGING TRENDS IN TYPE 2 DIABETES

    Carole  Gleeson

    Carole Gleeson, Principal Analyst , Wood Mackenzie Ltd

  • Global prevalence and emerging markets
  • Pipeline, unmet need, and future therapeutic landscape
  • Shifts in disease management
  • Trends in reimbursement
  • Ten-year market forecast
  • 11:40 PARTNERING STRATEGIES IN LICENSING FOR TYPE II DIABETES AND THE METABOLIC SYNDROME

  • Target identification and definition of target product profiles
  • Evaluation processes and valuation of early and advanced opportunities
  • Pros and Cons of Research Collaborations and Co-Development options as part of Licensing deals     
  • Johannes Zanzinger

    Johannes Zanzinger, Global Licensing Metabolic Diseases, Boehringer Ingelheim

    12:20 Networking Lunch

    13:50 NOVEL KINETIC ASSAYS FOR METABOLIC DRUG DISCOVERY

    David Ferrick

    David Ferrick, Vice President, Assay Development, Seahorse Bioscience Inc

    ·                     Simultaneous measurement of glycolysis and aerobic respiration
    ·                     Kinetic analyses of agonists that increase fatty acid oxidation
    ·                     Early indication of mitochondrial liabilities for new chemical entities

    14:30 GLUCOKINASE ACTIVATORS IN DIABETES MANAGEMENT

    Matthew Coghlan

    Matthew Coghlan, Candidate Drug Delivery Team Leader, Diabetes and Obesity Drug Discovery, AstraZeneca

    • Discovery of GKAs
    • In vitro characterisation of GKAs in cell models
    • In vivo mechanism of action and efficacy of GKAs in healthy animals and disease models
    • The opportunity for GKAs as novel anti-diabetic agents?

    15:10 Afternoon Tea

    15:40 MICRONUTRIENT DIETARY SUPPLEMENTATION SUPPORTS OBJECTIVE LABORATORY, CLINICAL AND QUALITY OF LIFE IMPROVEMENTS IN DIABETICS

    Reg McDaniel

    Reg McDaniel, Director, Research, Fisher Institute for Medical Research

    16:40 OXIDATIVE STRESS AND CARDIOVASCULAR COMPLICATIONS IN DIABETES

    Mustafa Lokhandwala

    Mustafa Lokhandwala, Executive Vice Dean of Research, University of Houston

  • Mechanism of oxidative stress in diabetes
  • Molecular mechanisms of oxidative stress-induced diabetic complications
  • Potential for antioxidant therapy in diabetes
  • Antioxidant properties of diabetic drugs
  • Oxidative Stress and Drug Receptor G-protein Interactions in Diabetes
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Jon Arch

    Jon Arch, Professorial Research Fellow & Deputy Director, Metabolic Research, University of Buckingham

    9:10 METABOLIC SYNDROME OPPORTUNITIES AND CHALLENGES

    Rebecca Taub

    Rebecca Taub, Vice President, Research & Metabolic Diseases, Hoffmann-La Roche

  • New FDA Guidelines: Potential for metabolic syndrome directed therapeutics?
  • Discovery of novel metabolic syndrome targets using RNAi
  • Early Pipeline Targets with potential to treat metabolic syndrome: DGAT1, SCD1, HSD1, THR and Gut Peptides
  • 9:50 FIGHTING DIABETES TYPE II WITH ‘EXPENDITURE GENES’

    Itzik Harosh

    Itzik Harosh, President & Chief Executive Officer, ObeTherapy Biotechnology

    • Is diabetes type II a disease or a consequence?
    • Are we treating the symptoms or the disease?
    • The paradox; why some obese people do not develop diabetes and why some lean individuals do
    • A new approach for identifying genes for diabetes treatment
    • A drug versus work-out regime

    10:30 Morning Coffee

    11:00 BASAL INSULIN TRANSDERMAL PATCH- CREATING HIGHER STANDARDS OF PATIENT CARE

    Eric Tomlinson

    Eric Tomlinson, President & Chief Executive Officer, Altea Therapeutics Corporation

    ·         Sustained and constant insulin delivery at therapeutic levels
    ·         Efficient delivery of insulin
    ·         Potential for lower risk of hypoglycemia and storage at room temperature
    ·         Anticipated greater patient compliance and earlier adoption of insulin in diabetes management

    11:40 THE USE OF BIOMARKERS FOR THE DISCOVERY AND DEVELOPMENT OF DIABETIC TREATMENTS

    Simon Westbrook

    Simon Westbrook, Associate Research Fellow, Biomarkers and Translational Biology, Pfizer

    ·                     Current use of biomarkers in drug discovery
    ·                     Impact of the use of biomarkers in the development of diabetic treatments
    ·                     Future of biomarkers for the treatment of Type I and II diabetes and their impact on the pharmaceutical industry

    12:20 Networking Lunch

    13:50 11B-HYDROXYSTEROID DEHYDROGENASE INHIBITORS: 10 YEARS AFTER THE KO MICE

    Joannes Linders

    Joannes Linders, Principal Scientist, Johnson & Johnson PRD REDEU

  • 11b-HSD1 inhibitors: a panacea for metabolic syndrome?
  • 11b-HSD1 KO mice and transgenics
  • 11b-HSD1 inhibitors Vs glucocorticoid antagonists
  • Drug discovery and 11b-HSD1 inhibitors: a problem with vivo models?
  • Pitfalls in the development of 11b-HSD1 inhibitors
  • 14:30 INSULIN SENSITIZATION WITHOUT WEIGHT GAIN: BLOCK OF GHRELIN SIGNALING

    Peter DiStefano

    Peter DiStefano, Chief Scientific Officer, Elixir Pharmaceuticals, Inc.

    15:10 Afternoon Tea

    15:40 TREATING VISCERAL OBESITY AND INSULIN RESISTANCE: NO NEED FOR POLYPHARMACY?

    Jon Arch

    Jon Arch, Professorial Research Fellow & Deputy Director, Metabolic Research, University of Buckingham

    ·                     Definitions of the metabolic syndrome
    ·                     Current treatments
    ·                     Causes: genes, early life programming and environment
    ·                     Rodent models
    ·                     Opportunities for intervention

    16:20 CRITICAL ASSESSMENT OF THE POTENTIAL OF CURRENT AND FUTURE ANTI-OBESITY DRUGS IN THE TREATMENT OF DIABETES

    Rob B Jones

    Rob B Jones, Director, RenaSci Consultancy Ltd

    ·                     Obesity as a major driver of diabetes
    ·                     Use of dietary-induced obesity rodent models of metabolic syndrome to evaluate drugs
    ·                     Relationship of preclinical results to clinical outcomes
    ·                     Current drugs eg, sibutramine, orlistat, rimonabant and new approaches, eg 5HT6 ligands, topiramate phentermine combination will be used as examples.  

    17:00 BETA CELL REGENERATION – A PROMISING APPROACH FOR THE TREATMENT OF DIABETES

    Cord Dohrmann

    Cord Dohrmann, Chief Scientific Officer, DeveloGen

  • Accumulating evidence for beta cell regeneration
  • Mechanisms of beta cell regeneration
  • Projects in development
  • DeveloGen’s approach to beta cell regeneration
  • 17:40 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    EFFECTIVE PRICING AND REIMBURSEMENT STRATEGIES FOR METABOLIC DRUGS
    Workshop

    EFFECTIVE PRICING AND REIMBURSEMENT STRATEGIES FOR METABOLIC DRUGS

    Crowne Plaza Hotel - The City
    31st October 2007
    London, United Kingdom

    Crowne Plaza Hotel - The City

    19 New Bridge Street
    London EC4V 6DB
    United Kingdom

    Crowne Plaza Hotel - The City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.